2006 proposed fee schedule - American Society of Clinical Oncology

The revisions read as follows:
§413.174 Prospective rates for hospital-based and
independent ESRD facilities.
* * * * *
370
(f) Additional payment for separately billable drugs.
CMS makes an additional payment for certain drugs furnished
to ESRD patients by a Medicare-approved ESRD facility. CMS
makes this payment directly to the ESRD facility. Payment
for these drugs is made--
(1) Only on an assignment basis, directly to the
facility which must accept, as payment in full, the amount
that CMS determines;
(2) Subject to the Part B deductible and coinsurance;
(3) To hospital-based facilities in accordance with
the cost reimbursement rules set forth in this part, except
for erythropoietin/epogen (commonly called EPO), which is
paid the same amount as independent facilities; and
(4) To independent facilities in accordance with the
methodology set forth in §405.517 of this chapter.
12. Section 413.180 is amended by--
A. Revising paragraphs (b) and (d)
B. Removing paragraphs (e) and (k).
C. Redesignationg paragraphs (f) through (j) as
paragraphs (e) through (i).